Plasma Serotonin in Heart Failure: Possible Marker and Potential Treatment Target

2017 ◽  
Vol 26 (5) ◽  
pp. 442-449 ◽  
Author(s):  
Ahmed M. Selim ◽  
Nitasha Sarswat ◽  
Iosif Kelesidis ◽  
Muhammad Iqbal ◽  
Ramesh Chandra ◽  
...  
Keyword(s):  
Heart Failure ◽  
Potential Treatment ◽  
Treatment Target ◽  
Plasma Serotonin

Gut Microbiota as a Potential Treatment Target in Patient with Chronic Heart Failure

2020 ◽  
Vol 2 (9) ◽  
pp. 1614-1627
Author(s):  
Joshua Henrina ◽  
Irvan Cahyadi ◽  
Hoo Felicia Hadi Gunawan ◽  
Leonardo Paskah Suciadi
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Gut Microbiota ◽  
Potential Treatment ◽  
Treatment Target

CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus

2022 ◽  
pp. 1-5
Author(s):  
Trine Engelbrecht Hybel ◽  
Maja Ølholm Vase ◽  
Kristina Lystlund Lauridsen ◽  
Marie Beck Enemark ◽  
Michael Boe Møller ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Potential Treatment ◽  
Treatment Target ◽  
Immunodeficiency Virus

The Skin Microbiome in Atopic Dermatitis—a Potential Treatment Target?

2018 ◽  
Vol 7 (4) ◽  
pp. 199-208
Author(s):  
Caroline Meyer Olesen ◽  
Maja-Lisa Clausen ◽  
Paal Skytt Andersen ◽  
Tove Agner
Keyword(s):  
Atopic Dermatitis ◽  
Skin Microbiome ◽  
Potential Treatment ◽  
Treatment Target

Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity

2021 ◽  
Author(s):  
Enyuan Cao ◽  
Matthew J. Watt ◽  
Cameron J. Nowell ◽  
Tim Quach ◽  
Jamie S. Simpson ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Potential Treatment ◽  
Treatment Target

Elevated Foxo3a and Fas‐ligand expression in human periapical granulomas as a potential treatment target

Oral Diseases ◽  
2021 ◽  
Author(s):  
Kae Ishii ◽  
Takahito Tamura ◽  
Keisuke Hatori ◽  
Kazuma Himi ◽  
Takeshi Nakamura ◽  
...  
Keyword(s):  
Fas Ligand ◽  
Potential Treatment ◽  
Treatment Target ◽  
Ligand Expression

Genetics of cardiomyopathies: myocardial infiltration

ESC CardioMed ◽  
2018 ◽  
pp. 710-713
Author(s):  
Frank Weidemann
Keyword(s):  
Heart Failure ◽  
Pompe Disease ◽  
Genetic Disease ◽  
Neurological Disease ◽  
Diastolic Filling ◽  
Potential Treatment ◽  
Infiltrative Cardiomyopathy ◽  
Storage Products ◽  
Storage Disorders

Genetic disease can lead to myocardial infiltration which results in a cardiomyopathy characterized by the deposition of storage products within ventricular walls. The storage is inducing diastolic filling abnormalities which are finally responsible for the symptoms such as dyspnoea. During follow-up most patients die because of heart failure. Transthyretin-related amyloidosis is the most common infiltrative cardiomyopathy. Rarer diseases are storage disorders such as Fabry disease and Pompe disease. The primary neurological disease Friedreich’s ataxia can in addition induce an infiltrative cardiomyopathy. This chapter focuses on the pathophysiology, the symptoms, the typical image findings, and the potential treatment of these different rare genetic infiltrative diseases.

Sign in / Sign up

Export Citation Format

Share Document